Endomucin inhibitor as an anti-angiogenic agent
AssigneeThe Schepens Eye Research Institute, Inc.
InventorsPatricia A. D'Amore, Magali Saint-Geniez, Cindy Park-Windhol
Life of this patent
Estimating the term…
Abstract
A method for reducing neovascularization in an ocular tissue is carried out by contacting the tissue with an inhibitor of endomucin expression or activity.
Claims27
A method for reducing neovascularization in an ocular tissue, comprising diagnosing a subject with aberrant angiogenesis in the eye and contacting said ocular tissue with an inhibitor of endomucin (EMCN) expression or activity, wherein said inhibitor comprises an endomucin-specific nucleic acid inhibitor, wherein said aberrant angiogenesis comprises age-related macular degeneration, diabetic retinopathy, retinopathy of prematurity, or ischemic retinal vein occlusion, and wherein said inhibitor is administered to said subject diagnosed as suffering from said age-related macular degeneration, diabetic retinopathy, retinopathy of prematurity, or ischemic retinal vein occlusion.
Dependencies are inferred from the claim text.